Orexo Achieves Significant Progress with OX390 in Groundbreaking In-Vivo Study

Orexo AB, a Swedish pharmaceutical company, has recently delivered encouraging findings from a pivotal in-vivo study concerning its investigational compound OX390. The study focuses on the nasal absorption of atipamezole, facilitated through Orexo's proprietary AmorphOX® delivery technology. This research marks an essential milestone for OX390, which is being developed as an emergency treatment tailored to counteract overdoses related to specific alpha-2 agonists, notably xylazine and medetomidine, substances commonly referred to as "Tranq" and "Rhino Tranq."

Promising Study Outcomes

The findings from the pre-clinical study demonstrate rapid and effective nasal absorption of atipamezole, successfully affirming proof-of-concept across various formulations. Impressively, a single intranasal dose of OX390 has shown to achieve drug exposure levels within the targeted therapeutic range, underscoring the viability of this treatment approach.

Following these positive results, Orexo is preparing for a type C meeting with the FDA to finalize the non-clinical development plan that will set the stage for subsequent human clinical trials. Dr. Ed Kim, Orexo's Chief Medical Officer, expressed his optimism, stating that OX390 could serve as a life-saving intervention against the rising threat of overdoses involving xylazine and medetomidine.

As overdose incidents related to alpha-2 agonists grow increasingly prevalent in the United States, the demand for effective treatments has never been more pressing. Orexo positions itself at the forefront of medical innovation by pioneering solutions like OX390, demonstrating a commitment to addressing urgent public health challenges effectively.

Nikolaj Sorensen, CEO and President of Orexo, reaffirmed the importance of the in-vivo study results, emphasizing both OX390’s potential and the efficacy of the AmorphOX technology. With the study confirming rapid absorption and high bioavailability associated with nasal delivery, Orexo is firmly committed to advancing OX390's development.

The Need for OX390

The impetus to develop OX390 arose from growing evidence that existing opioid antagonists, such as naloxone, may not be sufficient in reviving individuals suffering from opioid-induced respiratory depression, especially when compounded by illicit drug adulteration. By harnessing the unique characteristics of atipamezole and the AmorphOX delivery mechanism, Orexo aims to create a swift-acting intranasal powder intended for immediate use by first responders and non-professionals in the community.

About OX390 and AmorphOX

OX390 is under investigation and is thus not yet FDA approved for human use. The AmorphOX platform, on which OX390 is built, integrates a specialized powder made from a unique combination of drug components and carrier materials, ensuring superior chemical and physical stability along with rapid drug dissolution. This innovative technology can be applied to a broad range of active ingredients, enhancing both bioavailability and systemic effectiveness as evidenced in several human clinical trials.

With an extensive history of drug approvals and a robust pipeline of developmental projects, Orexo is on a path of innovation, addressing critical healthcare needs both in Sweden and globally. The company operates from Uppsala, Sweden, and has a subsidiary in New Jersey, USA. Orexo’s advancements reflect a strong vision of bringing essential treatments to market aimed at combating severe health conditions.

For further updates on Orexo's developments and research initiatives, individuals can visit Orexo's website or follow the company on various social media platforms. The outcome of the ongoing studies and meetings with the FDA will undoubtedly shape the future landscape of emergency treatments for opioid overdoses and influence public health strategies significantly.